TOKYO, Mar 12 (Pulse News Wire) – Feed ONE CO.,LTD. (206A.T) and Receptor.AI Inc.
Entered into a drug discovery collaboration aimed at developing novel small molecule drugs targeting protein-protein interactions (PPI) and membrane proteins. The agreement was signed, and will leverage PRISM's PepMetics technology and Receptor.AI’s advanced AI navigation engine. Under the pact, PRISM and Receptor.AI will combine their proprietary technologies to explore innovative compounds, lead molecules, and clinical candidates. Initially focusing on metabolic disease targets, the companies plan to expand opportunities for joint research with pharmaceutical firms interested in leveraging their combined expertise.
"We are delighted to partner with Receptor.AI," said Takahara Dai, President of PRISM BioLab. "This collaboration will enhance our ability to develop effective treatments based on solid scientific evidence." Receptor.AI's Founder & CEO, Dr. Alan Nafiiev, emphasized the potential of integrating QuorumMap, a chemical space navigation engine, with PRISM's high-quality compound library to accelerate the drug development process. Both companies aim to create synergies through the integration of cutting-edge methodologies, fostering innovation and advancing their respective drug discovery capabilities.
The impact on PRISM BioLab's fiscal year ending September 30, 2026, is expected to be minor but could contribute to long-term growth and value enhancement.
🟡 Confidence: Standard AI-translated content.